This is a post from Former Pfizer VP, Dr. Mike Yeadon. Very interesting. It’s all coming true after the jabs.
I’ve predicted autoimmune responses after injection with mRNA encoding non-self proteins.
I didn’t say “you’ll see an increase in a particular, well-defined autoimmune disorder”.
If a person is generally unwell after injection, unless they’re looking for an autoimmune underpinning to their illness, it doesn’t announce itself.
Also, we know from other investigations that a high proportion of these injections do not contain what’s on the label, sometimes no mRNA at all. Hardly able to trigger autoimmune attacks.
So I find it staggering that they’re admitting to a 46% increase in incidence of defined autoimmune diseases after “vaccination”.
We’ll be inventing all manner of new autoimmune syndromes, most of which haven’t previously been diagnosed.
Imagine being injected with ten such shots over a few years?
“You’ll own nothing and you’ll hardly notice, since you’ll be permanently unwell and then perish”.
I appreciate it doesn’t roll off the tongue.
Best wishes,
Mike
Incident autoimmune diseases in association with a SARS-CoV-2 infection: A matched cohort study
Abstract
Objectives To investigate whether the risk of developing an incident autoimmune disease is increased in patients with previous COVID-19 disease compared to people without COVID-19.
Method A cohort was selected from German routine health care data covering 38.9 million individuals. Based on documented diagnoses, we identified individuals with polymerase chain reaction (PCR)-confirmed COVID-19 through December 31, 2020. Patients were matched 1:3 to control patients without COVID-19. Both groups were followed up until June 30, 2021. We used the four quarters preceding the index date until the end of follow-up to analyze the onset of autoimmune diseases during the post-acute period. Incidence rates (IR) per 1000 person-years were calculated for each outcome and patient group. Poisson models were deployed to estimate the incidence rate ratios (IRRs) of developing an autoimmune disease conditional on a preceding diagnosis of COVID-19.
Results In total, 641,704 patients with COVID-19 were included. Comparing the incidence rates in the COVID-19 (IR=15.05, 95% CI: 14.69-15.42) and matched control groups (IR=10.55, 95% CI: 10.25-10.86), we found a 42.63% higher likelihood of acquiring autoimmunity for patients who had suffered from COVID-19. This estimate was similar for common autoimmune diseases, such as Hashimoto thyroiditis, rheumatoid arthritis, or Sjögren syndrome. The highest IRR was observed for autoimmune disease of the vasculitis group. Patients with a more severe course of COVID-19 were at a greater risk for incident autoimmune diseases.
Conclusions SARS-CoV-2 infection is associated with an increased risk of developing new-onset autoimmune diseases after the acute phase of infection.